were significantly higher during therapy than when compared to both before therapy ($p<0.00001$) and after therapy ($p=0.0002$) but levels before therapy were not significantly different from post therapy. Elevated scores on therapy were attributable to an increase in mean HA ($p<0.0002$) and P3NP ($p<0.01$) levels on therapy, whereas a significant change in mean TIMP-1 during therapy was not seen. These elevations were seen in all patients regardless of changes in histological fibrosis after therapy ($n=20$ decrease, $n=25$ no change, $n=35$ increase in Ishak stage). However, individual changes in TIMP1 ($r=0.239$, $p=0.04$) and changes in ELF ($r=0.315$, $p=0.004$) from pre- to post-therapy levels were found to correlate with the change of Ishak fibrosis stage before and during treatment.

Conclusion During interferon-based therapy, levels of HA and P3NP and the ELF score rise globally and subsequently fall to values similar to those seen prior to therapy regardless of fibrosis evolution, while TIMP1 levels remained unaffected. However, ELF scores pre and post therapy did accurately reflect changes in histology. This suggests that ELF scores and non-invasive panels incorporating HA and P3NP should be interpreted with caution during interferon-based therapy.

Abstract PMO-172 Figure 1 Fibrosis evolution compared to changes in mean ELF score during interferon therapy.

Competing interests None declared.

PMO-173 DISTRICT GENERAL HOSPITAL NETWORKS CAN PROVIDE SAFE AND EFFECTIVE HEPATITIS C TREATMENT: RESULTS OF A 4-YEAR AUDIT

doi:10.1136/gutjnl-2012-302514b.173

¹T Hydes, ²H Allen, ²S Al-Shamma, ³C Hovell, ¹N Sharer, ²E Williams. ¹Gastroenterology & Hepatology, Poole Hospital NHS Foundation Trust, Poole, UK; ²Gastroenterology & Hepatology, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK; ³Gastroenterology & Hepatology, Dorset County Hospital NHS Foundation Trust, Dorchester, UK

Introduction Chronic Hepatitis C (CHC) treatment is well described in the context of Randomised Controlled Trials (RCTs).¹ Whether these findings can be extrapolated to treatment programmes delivered by nurse specialists working in District General Hospitals (DGHs) is unclear.

Methods The Dorset Viral Hepatitis Network has a catchment area of 750 000 people. Patients are assessed and treated in three DGHs by a team of nurse specialists working under the supervision of four lead clinicians. Between January 2007 and January 2011 standard of care for CHC treatment was Ribavirin and Pegylated Interferon α 2a given for 24 weeks (G2/3 patients) to 48 weeks (G1/4). A retrospective analysis of the network's reference database was undertaken focusing on treatment naïve patients.

Results In total 207 treatment naïve patients received antiviral therapy. Mean age at time of treatment was 43 years (20–66); 74% (154) were male and 67% (139) acquired CHC through injection drug use. G1 patients represented 49% (102) of the cohort; 3% (6) were Hepatitis B/HIV co-infected and 95% (196) were Caucasian. A clinical or histological diagnosis of cirrhosis was present in 8% (16). In total 12% (24) moved out of area or were lost to follow-up within 24 weeks of completing treatment. Based on intention to treat, Sustained Virological Response rates (undetectable HCV RNA in serum 24 weeks post treatment) were comparable to those derived from RCT¹ data (Abstract PMO-173 table 1). Non-response was observed in 11% (11/102), 5% (5/98) and 14% (1/7) of G1, G2/3 and G4 patients respectively. Breakthrough or relapse was observed in 18% (18/102), 13% (13/98) and 14% (1/7) of G1, G2/3 and G4 patients respectively. Overall 1% (3) of patients discontinued treatment as a result of a laboratory abnormality and 12% (24) because of other medical complications or side effect intolerance. These proportions are comparable to those observed in RCTs ($p=0.735$, $p=0.146$).

Abstract PMO-173 Table 1 Comparison of SVR rates between centres

Genotype	SVR in DGH practice	SVR in RCT ¹ *	p Value†
Genotype 1	46% (47/102)	41% (241/583)	0.37
Genotype 2/3	60% (59/98)	68% (194/285)	0.16
Genotype 4	57% (4/7)	58% (14/24)	0.96

*51% Received Peg IFN α 2a.

†Derived from χ^2 test.

Conclusion Specialist nurses supported by a network of DGHs can deliver a high quality Hepatitis C service across a broad geographical area. These findings are encouraging when considering a move towards community based CHC management.

Competing interests None declared.

REFERENCE

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *New Engl J Med* 2002; **347**:975–82.

PMO-174 INTRAHEPATIC NATURAL KILLER CELL PHENOTYPING AND FUNCTIONAL ANALYSIS BY FINE NEEDLE ASPIRATION IN CHRONIC HCV INFECTION

doi:10.1136/gutjnl-2012-302514b.174

T Pembroke, * E Wang, A Gallimore, A Godkin. School of Medicine, Cardiff University, Cardiff, UK

Introduction Hepatitis C virus (HCV) infection results in chronic infection in the majority of subjects, indicating viral immunoevasion strategies. Treatment with interferon alpha (IFN α) stimulates the immune system but the role of NK cells remains unclear.

Methods Intra-hepatic NK cells were obtained from 20 HCV infected donors prior to treatment and 16 non-viral chronic liver disease (CLD) patients along with paired peripheral blood samples. NK phenotype (CD16, NKp30, NKp46, NKG2D and NKG2A) and functional profile (Ki67, CD107a, IFN- γ and Granzyme B) was assessed by flow cytometry. In a separate cohort of 8 HCV patients, who had completed treatment, rate of viral clearance was calculated and pre-treatment peripheral blood NK phenotype and CD107a expression in response to increasing stimulation was measured. At low-level stimulation peripheral blood mononuclear cells (PBMCs) were incubated overnight with 50 u/ml IFN α and exposed to Huh7. Five target cells and at maximal stimulation PBMCs were incubated with 1000 u/ml IFN α and K562 target cells.